Post-Concussion Sleep and Brain-heart Functions

1. Background and Rationale

Up to 50% of individuals who sustain a concussion experience sleep disturbances. Poor sleep has been found predictive of poorer outcomes in post-concussion recovery. In Canada, insomnia constitutes a major burden upon public health. Insomnia not only impairs sleep quality but also exacerbates cognitive, emotional, and physiological post-concussion symptoms, including cardiovascular dysfunctions, such as elevated heart rate and sympathetic overactivation; thus, possibly leading to delayed recovery following a concussion. Furthermore, recent work in chronic insomnia identified increased levels of brain microstructure injury biomarkers previously linked to concussion. These disruptions can potentially interfere with brain-heart functions and delay post-concussion recovery. As such, treating insomnia may result in better post-concussion recovery, which may notably be observable through biomarkers linked to brain-heart health.

Cognitive-Behavioural Therapy treatment for insomnia (CBT-I) is the first line of treatment recommended for chronic primary insomnia sufferers. It combines multipronged strategies involving education and progressive personalized sleep manipulations to address the maladaptive cognitive and behavioural processes contributing to the maintenance of insomnia. Five distinct intervention components - stimulus control, time in bed restriction therapy, psychoeducation about sleep, cognitive therapy, and relaxation training - are included within the CBT-I framework. CBT-I has been found effective to address sleep issues emerging after a concussion, with documented benefits for post-concussion recovery. This may notably operate via the restoration of brain-heart functions since CBT-I enhances brain functions following concussions, may influence autonomic regulation by reducing hyperarousal and sympathetic overactivation, and improves cardiovascular outcomes.

One of the putative mechanisms of action of CBT-I resides in increased deep sleep due to enhanced sleep pressure. Deep sleep is a state characterized by high amplitude low frequency brain activity in the delta frequency range on the electroencephalogram (EEG). Recent discoveries highlight the role of deep sleep in autonomic regulation and healing processes. Post-concussion sleep has been associated with increased deep sleep. One may postulate that higher increases in delta activity driven by CBT-I may be associated with enhanced autonomic functions and post-concussion symptoms recovery.

The investigators recently expanded previous results suggesting that individuals with insomnia have low coherence between brain and heart activity. To the best of our knowledge, research has yet to investigate whether successful insomnia treatment, through CBT-I, restores brain-heart interactions, and how changes in brain, heart, and brain-heart interactions may relate to post-concussion symptoms recovery following CBT-I. 2. Study Objectives

Primary objective:

• Evaluate the efficacy of a digital CBT-I program adapted for post-concussion syndrome (CBT-pI) on insomnia symptoms (primary outcome) and biomarkers related to post-concussion brain-heart function (secondary outcomes)

Secondary objectives: * Evaluate treatment acceptability and satisfaction * Collate feedback about potential adaptations to better address challenges linked to insomnia treatment in the context of post-concussion brain-heart function * Explore putative brain-heart mechanisms associated with CBT-pI responses based on EEG markers, heart rate and heart rate variability, sleep-based EEG-ECG interactions, and cognitive performance 3. Methods

3.1. Contact Pathway Participants will be recruited through the 360 Concussion Care (360CC) clinic. The participants will be referred by clinicians at this clinic to members of the research team. Clinicians will identify patients they would like to refer to the study, request that these patients fill out the "Permission to be contacted form", and send this form to the research team. A research assistant will then contact the potential participant through email to send them a summary of the study and a link to complete an anonymous online screening form for the first set of eligibility criteria on a secured web platform (Qualtrics, www.qualtrics.com; license held via the University of Ottawa) and a unique identification code. The first question of this online form will ask participants to confirm their consent to take part in the screening process. This will be documented in the screening database. The second question of this online screening form will ask participants to insert their unique anonymous research screening code. This screening form will notably include items assessing neurologic and psychiatric history and medications, and will include the Sleep Condition Indicator (SCI), WHO-ASSIST item 2, Sleep Disorders Symptoms Checklist-25 (SDS-CL-25), and Epworth Sleepiness Scale. It should take between 10 and 15 minutes to complete.

3.2. Ongoing Consent Procedure For participants found to be eligible after the screening, the research assistant will call participants to summarize the next steps of the study verbally and address any questions or concerns that participants may have. At which point, verbal consent will be obtained to conduct a structured interview using the Mini International Neuropsychiatric Interview (M.I.N.I) and the insomnia module of the SCID to determine the last set of eligibility criteria.

After this interview, eligible participants will be sent an electronic form containing the information and consent form (ICF) and will have as much time as the participant needs to read it at home before enrolling in the study. As part of that same electronic form, the participant will confirm consent by ticking consent boxes and entering their full name. This information will be stored in a consent database showing the participant's full name and consent date, which will be kept on restricted-access folders on the ROMHC's server in separate files than the research data. This online consent form was created based on published guidelines from peer-reviewed articles. Special care will be given to ensure that participants understand that their participation is entirely voluntary and that the participant can withdraw from the study at any stage (without any consequence on the treatment\[s\] they receive at the 360CC clinic or their relationship with any of the clinicians at the 360CC clinic).

At each follow-up assessment stage, participants will provide consent via an electronic form before completing the online assessment battery; thus, ongoing consent will be documented at each follow-up time point. The consent procedure will consist of the same process as outlined above - participants will confirm their consent electronically by ticking consent boxes and entering their full name. The investigators will store this information in the consent database.

3.3. Pre/post-intervention Assessments Eligible participants will receive the research equipment by mail and attend a video call appointment (on a secured uOttawa Zoom platform). Participants who are able and willing to come on-site will be invited to do this visit in person at the Sleep Research Unit of the ROMHC rather than over Zoom.

During this first appointment, a research assistant will instruct participants on how to use the study equipment. Participants will also be provided with a brief pre-recorded online video explaining how to use the equipment. The study equipment will include a digital sleep log (containing the core elements of the ''Consensus Sleep Diary'') on the study smartphone app to be filled for 14 days at four time points: baseline (before the intervention starts), post-intervention (after the last treatment week), follow-up 1 (1 month after treatment), and follow-up 2 (6 months after treatment). Participants may fill out the daily sleep log on paper to reduce screen time, if needed. During the last 7 nights of time points 1, 2 and 3, participants will wear. a portable EEG and heart rate headband device (InteraXon, Toronto, Canada). Participants will be informed that they will be able to contact the research assistant at any point throughout the study trial if the participant has any questions and/or concerns.

Participants will complete assessment questionnaires on a secured web-platform (Qualtrics, licensed to the University of Ottawa) at the four time points. These questionnaires should last about 20-30 minutes (see table 1) and will inquire about general demographic and clinical information (including all treatments received for sleep and post-concussion symptoms), sleep, daytime functioning, post-concussion symptoms, mental health, medication use, psychological treatments, and perceptions about the EEG headband. If required, patients can break this up into briefer sessions. The day after the last intervention session, the questionnaire pack will be supplemented by scales assessing treatment adherence and satisfaction (about 5 additional minutes). At the same four time points, participants will be invited to undergo brief cognitive testing on the same online app that will be used for the intervention.

3.4. Collating data from the 360 Concussion Care clinics By consenting to take part to the study, participants will consent for their data, collected as part of the 360 Concussion Care clinics (i.e., our recruitment site) and the TRANSENDENT Concussion Research Program that is taking place through the clinics, to be used in the current study. This consent will be obtained explicitly through the information and consent form. This includes: (1) autonomic measures (e.g. heart rate and blood pressure, tilt test results), (2) aerobic exercise tolerance (Buffalo Concussion Bike Test \[BCBT/ Buffalo Concussion Treadmill Test (BCTT\]), (3) pupillometry, (4) eye-tracking, (5) salivary fluid (i.e., micro\[mi\] RNAs) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below), (6) blood (i.e., inflammatory markers) to assess physiological biomarkers of concussion symptomology (see description of relevance in paragraph below, and (7) advanced neuroimaging (MRI), (8) results from questionnaires, diagnoses, and treatment plans (see TRANSCENDENT protocol paper).

3.5. Experimental Conditions Following the pre-intervention assessment, participants will be randomly assigned to one of two arms: an active intervention (CBT-pI) or a control intervention (sleep hygiene), both of which will be delivered on the same digital infrastructure that could be accessed either via a mobile phone or computer (i.e. online app). Their account on this online app will not contain any identifiable information, only an anonymous research participant identification code.

Randomization and blinding:

The randomization process will be done by a computer-generated randomizer, stratified by sex. This will be managed by a research collaborator who will not be directly involved in clinical assessments or data processing. All researchers involved in clinical assessments or data processing will be blinded to the assignment of these different conditions.

Active Intervention:

The digital CBT-pI program is co-developed with lived experts with a history of post-concussion insomnia and is inspired from published recommendations and existing evidence-based CBT-pI programs. It includes four bi-weekly sessions lasting about 30-45 minutes covering all core elements of CBT-I, with some adaptations tailored to better serve people with post-concussion symptoms. For instance, the app design will account for light, sound, and visual field motion sensitivity (e.g. light enlarged text fonts on dark background colours, amber filters, sound processing to lower high pitch tones, minimized scrolling, and slow screen transitions). Participants will be advised to use a large font, reduce the

• Satisfaction with treatment effectiveness as measured with the Modified Treatment Satisfaction Questionnaire for Medication [Срок оценки: 10 weeks]
• Satisfaction with treatment effectiveness as measured by the Modified Treatment Satisfaction Scale [Срок оценки: 10 weeks]
• Changes in insomnia symptoms [Срок оценки: From baseline (week 0) to the first follow-up (week 14)]
• Changes in insomnia symptoms [Срок оценки: From baseline (week 0) to the last follow-up (week 34)]
• Treatment acceptability as measured by the Treatment Acceptability/Adherence Scale [Срок оценки: 10 weeks]
• Portable electroencephalogram (EEG) feedback [Срок оценки: From baseline (week 0) to post-intervention (week 10)]
• Assess feedback of potential adaptations linked to insomnia treatment [Срок оценки: 10 weeks]
• Changes in EEG-based sleep latency [Срок оценки: From baseline (week 0) to follow-up (week 14)]
• Changes in EEG-based latency to REM sleep [Срок оценки: From baseline (week 0) to follow-up (week 14)]
• Changes in EEG-based total sleep time [Срок оценки: From baseline (week 0) to follow-up (week 14)]
• Changes in EEG-based slow wave activity [Срок оценки: From baseline (week 0) to follow-up (week 14)]
• Changes in EEG-based slow wave sleep [Срок оценки: From baseline (week 0) to follow-up (week 14)]